Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. (ACOG) shares were purchased by Opaleye, L.P.: 17,117 common shares on October 22, 2026, at a weighted average price of $8.3266, and 14,973 shares on October 23, 2026, at a weighted average price of $8.2344. Opaleye Management Inc., the reporting person and a ten percent owner, is the fund’s investment manager and disclaims beneficial ownership except to the extent of its pecuniary interest. Separately, the Managed Account was reported as holding 100,000 shares on October 22, 2026. No Rule 10b5-1 plan is reported.
Alpha Cognition Inc. ten-percent owner Opaleye Management Inc. reported indirect purchases of common shares by Opaleye, L.P. On October 16, 2026, Opaleye, L.P. purchased 14,283 shares at a weighted-average price of $8.2337 per share, with transaction prices ranging from $8.11 to $8.45. On October 15, 2026, it purchased 22,657 shares at a weighted-average price of $8.4289 per share, with transaction prices ranging from $8.35 to $8.49. No Rule 10b5-1 plan is reported. Opaleye Management Inc. says it may be deemed to beneficially own the Fund’s shares as investment manager and disclaims beneficial ownership except to the extent of its pecuniary interest.
Alpha Cognition Inc. (ACOG) reported that Opaleye, L.P. purchased 19,050 common shares on October 1, 2026, at a weighted average price of $8.6947 per share. No Rule 10b5-1 plan is reported. After the purchase, Opaleye, L.P. held 3,222,954 shares; a separate managed account held 100,000 shares as of October 1, 2026. Opaleye Management Inc., identified as a ten percent owner, may be deemed to beneficially own securities held by the Fund and Managed Account in its respective management roles, but disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Opaleye Management Inc., identified as a 10% owner of Alpha Cognition Inc. (ACOG), reported two common-stock purchases by Opaleye, L.P.: 13,426 shares at $8.47 on September 25, 2026, and 18,337 shares at a weighted average price of $8.5664 on September 24, 2026. The September 24 purchases ranged from $8.52 to $8.57. Opaleye Management disclaimed beneficial ownership except to the extent of its pecuniary interest. Separately, a Managed Account held 100,000 shares as of September 24, 2026.
Alpha Cognition Inc. ownership was reported by five reporting persons. Manchester Management Company, LLC and Manchester Management PR, LLC each reported beneficial ownership of 1,524,255 shares (6.9%); Manchester Explorer, L.P. reported 1,348,255 shares (6.1%). James E. Besser reported 1,639,255 shares (7.4%), including 115,000 with sole voting and dispositive power and 1,524,255 with shared power. Morgan C. Frank reported 1,393,255 shares (6.3%), including 45,000 with sole voting and dispositive power and 1,348,255 with shared power.
The reported securities are directly owned by advisory clients of Manchester Management PR, LLC. Among those clients, only Manchester Explorer, L.P. may be deemed to beneficially own more than 5% of the common stock. Each reporting person disclaims beneficial ownership except to the extent of its or their pecuniary interest.
Alpha Cognition Inc. (ACOG) reported that large shareholder Opaleye Management Inc., through entities it manages, purchased a total of 123,918 shares of Alpha Cognition common stock in open-market or private transactions on September 14–16, 2026. The purchases were made indirectly via Opaleye, L.P. and a separately managed account, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. (ACOG) director Robert James Wills purchased 10,000 Common Shares on 2026-08-21 in a purchase in open market or private transaction at a price of $9.62 per share. Following this transaction, he directly owns 32,241 Common Shares of Alpha Cognition Inc.
Alpha Cognition Inc. reported strong top-line growth in the quarter ended June 30, 2026 as its Alzheimer’s drug ZUNVEYL scaled. Total revenue rose to $6.1 million for the quarter and $9.6 million year-to-date, driven by higher prescription volumes and a higher wholesale acquisition cost of $869.36 per month.
Gross profit grew to $5.7 million in the quarter, but the company remains unprofitable as it invests in commercialization and development. Net loss was $8.8 million for the quarter and $15.3 million for the first half of 2026. Operating expenses reached $13.5 million in Q2, led by selling, general and administrative spending of $11.4 million and research and development of $2.0 million.
Cash and cash equivalents were $41.4 million against current liabilities of $6.4 million, with operating cash outflow of $18.7 million in the first half. Management believes current cash will fund operations for at least 12 months but expects to seek additional capital, including use of a $75 million at-the-market facility that has not yet been utilized.
Alpha Cognition Inc. reported that Opaleye Management Inc., a ten percent owner, through Opaleye, L.P. purchased 50,000 shares of common stock on August 3, 2026 at $8.00 per share and 2,900 shares on July 31, 2026 at a weighted average price of $7.9226 per share, with trades between $7.855 and $7.95. Opaleye Management also reported 100,000 shares held indirectly through a separately managed account and disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Alpha Cognition Inc., reported an indirect purchase of 130 shares of common stock at $7.90 per share on July 24, 2026, through Opaleye, L.P., bringing that fund's reported holdings to 2,995,323 shares.
Opaleye Management also reports indirect holdings of 100,000 shares in a separately managed account and disclaims beneficial ownership beyond its pecuniary interest.